Mateusz Kurek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4605043/publications.pdf

Version: 2024-02-01

623188 642321 24 974 14 23 citations g-index h-index papers 25 25 25 1176 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Fused Deposition Modeling as a Possible Approach for the Preparation of Orodispersible Tablets. Pharmaceuticals, 2022, 15, 69.	1.7	9
2	How Does Long-Term Storage Influence the Physical Stability and Dissolution of Bicalutamide from Solid Dispersions and Minitablets?. Processes, 2022, 10, 1002.	1.3	O
3	Poly(Vinyl Alcohol) Cryogel Membranes Loaded with Resveratrol as Potential Active Wound Dressings. AAPS PharmSciTech, 2021, 22, 109.	1.5	18
4	How to Obtain the Maximum Properties Flexibility of 3D Printed Ketoprofen Tablets Using Only One Drug-Loaded Filament?. Molecules, 2021, 26, 3106.	1.7	10
5	How Does the Addition of Kollidon®VA64 Inhibit the Recrystallization and Improve Ezetimibe Dissolution from Amorphous Solid Dispersions?. Pharmaceutics, 2021, 13, 147.	2.0	16
6	New multifunctional compounding mixer Farmacja Polska, 2021, 77, 591-600.	0.1	0
7	Molecular dynamics, viscoelastic properties and physical stability studies of a new amorphous dihydropyridine derivative with T-type calcium channel blocking activity. European Journal of Pharmaceutical Sciences, 2020, 141, 105083.	1.9	8
8	Speed it up, slow it down…An issue of bicalutamide release from 3D printed tablets. European Journal of Pharmaceutical Sciences, 2020, 143, 105169.	1.9	41
9	How Does the CO2 in Supercritical State Affect the Properties of Drug-Polymer Systems, Dissolution Performance and Characteristics of Tablets Containing Bicalutamide?. Materials, 2020, 13, 2848.	1.3	2
10	Multivariate Design of 3D Printed Immediate-Release Tablets with Liquid Crystal-Forming Drugâ€"Itraconazole. Materials, 2020, 13, 4961.	1.3	20
11	Compression-Induced Phase Transitions of Bicalutamide. Pharmaceutics, 2020, 12, 438.	2.0	13
12	How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions. European Journal of Pharmaceutical Sciences, 2019, 136, 104947.	1.9	22
13	The Self-Assembly Phenomenon of Poloxamers and Its Effect on the Dissolution of a Poorly Soluble Drug from Solid Dispersions Obtained by Solvent Methods. Pharmaceutics, 2019, 11, 130.	2.0	25
14	Influence of Polymeric Additive on the Physical Stability and Viscoelastic Properties of Aripiprazole. Molecular Pharmaceutics, 2019, 16, 1742-1750.	2.3	16
15	Enhanced dissolution of solid dispersions containing bicalutamide subjected to mechanical stress. International Journal of Pharmaceutics, 2018, 542, 18-26.	2.6	17
16	Spatiotemporal characterization of hydration process of asymmetric polymeric wound dressings for decubitus ulcers. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2018, 106, 843-853.	1.6	2
17	Molecular Disorder of Bicalutamideâ€"Amorphous Solid Dispersions Obtained by Solvent Methods. Pharmaceutics, 2018, 10, 194.	2.0	15
18	3D printing of tablets containing amorphous aripiprazole by filaments co-extrusion. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 44-47.	2.0	43

#	Article	IF	CITATION
19	3D Printing in Pharmaceutical and Medical Applications – Recent Achievements and Challenges. Pharmaceutical Research, 2018, 35, 176.	1.7	428
20	3D printed orodispersible films with Aripiprazole. International Journal of Pharmaceutics, 2017, 533, 413-420.	2.6	182
21	Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide. International Journal of Pharmaceutics, 2017, 533, 470-479.	2.6	36
22	PRINTING TECHNIQUES: RECENT DEVELOPMENTS IN PHARMACEUTICAL TECHNOLOGY. Acta Poloniae Pharmaceutica, 2017, 74, 753-763.	0.3	16
23	Preparation of solid self-emulsifying drug delivery systems using magnesium aluminometasilicates and fluid-bed coating process. Powder Technology, 2014, 266, 329-339.	2.1	22
24	Novel method for screening of enteric film coatings properties with magnetic resonance imaging. International Journal of Pharmaceutics, 2013, 456, 569-571.	2.6	10